<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02429427</url>
  </required_header>
  <id_info>
    <org_study_id>C/20/01</org_study_id>
    <nct_id>NCT02429427</nct_id>
  </id_info>
  <brief_title>European Celecoxib Trial in Primary Breast Cancer</brief_title>
  <acronym>REACT</acronym>
  <official_title>A Phase III Multicentre Double Blind Randomised Trial of Celecoxib Versus Placebo in Primary Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institute of Cancer Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It has been found that the chemical changes that take place in a patient's body during the
      development of inflammation may provide an environment which stimulates cancer cells. One
      step in the development of inflammation is the production of certain chemical substances
      which are important in the formation and spread of tumours. These are called prostaglandins.
      Cyclo-oxygenase II (COX-2) is an enzyme (a substance that speeds up chemical changes in the
      body) involved in the production of these prostaglandins and although it is not usually
      present in most tissues it is made at the sites of inflammation. Celecoxib is a selective
      Non-Steroidal Anti Inflammatory Drug (NSAID) which works by blocking the action of the COX-2
      enzyme, leading to a decrease in the production of prostaglandins and a reduction in
      inflammation.

      The purpose of this study is therefore to find out if celecoxib can be used after breast
      cancer treatment (chemotherapy and/ or radiotherapy) to reduce inflammation and thus reduce
      the ability of new tumours to grow and survive.

      2590 women with primary breast cancer will be recruited in this study from several locations
      in the United Kingdom and Germany. Eligible patients will be randomly allocated a treatment
      group, which can be celecoxib or placebo. Both treatments are taken orally (celecoxib 400mg
      daily, placebo 2 tablets daily) for a total of 2 years. In addition, hormone receptor
      positive patients will receive endocrine treatment as per local practice. Patients will
      prematurely discontinue treatment with celecoxib/placebo if disease progression is confirmed
      or if patients experience unacceptable toxicity.

      Patients will be seen every 6 months for the first 3 years and then off treatment follow-up
      is carried out annually. Participating patients will also be given the option to take part in
      the pathology sub-study by donating a sample of the tumour tissue collected at the time of
      the primary surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It has long been recognised that there is an association between chronic immune activation
      and cancer but the mechanisms behind this observation are not fully understood. The
      inflammatory process may provide an environment for development of malignant disease, with
      mediators of inflammatory response such as the cyclo-oxygenases playing an important role and
      providing a target for therapeutic intervention.

      Prostaglandins (PGs) are synthesised from phospholipids by the action of phospholipase A2 and
      cyclo-oxygenases. Cyclo-oxygenase (COX) -1 differs from COX-2 in that the latter is inducible
      and its expression is induced by a large range of oncogenes and growth factors. Celecoxib is
      a selective COX-2 inhibitor that does not cause the effects of COX-1 inhibition, namely
      gastrointestinal ulceration.

      The key regulatory step in this process is the enzymatic conversion of fatty acids to PGG2
      and PGH2 by COX. PGH2 is subsequently converted to one of several structurally related PGs
      including PGE2, PGD2, PGF2, and thromboxane A2 (TxA2), by the activity of specific PG
      synthases. PGs have important functions in every organ system and regulate a variety of
      physiological functions such as immunity, maintenance of vascular integrity and bone
      metabolism. COX-2 is not normally expressed in most tissues, but is induced by a wide
      spectrum of growth factors and pro-inflammatory cytokines in specific pathophysiological
      conditions. The expression of COX-2 is highly induced in cells transformed with the oncogene
      v-src or treated with phorbol esters.

      Several studies have suggested an association between non-steroidal anti-inflammatory drug
      (NSAID) consumption and decreased breast cancer risk.

      Elevated COX expression in breast cancer was suggested some time ago by the finding of
      elevated PG production in breast tumours.

      There is pharmacological and genetic evidence to indicate that a significant component of the
      anticancer property of NSAIDs is due to their ability to inhibit the COX-2 enzyme.

      This phase III randomised study assesses the impact on disease free survival and overall
      survival of the Cox-2 inhibitor Celecoxib as maintenance therapy following surgery and
      chemotherapy in the treatment of primary breast cancer.

      2590 women with primary breast cancer will be recruited in this study from several locations
      in the United Kingdom and Germany.

      Prior to randomization all patients should have completed at least 4 cycles of (neo) adjuvant
      chemotherapy. Patients who satisfy all the eligibility criteria for the study will be
      informed and consented to join the study. The Local Investigator will then contact the ICCG
      randomization centre to randomize the patient by fax or by telephone.

        1. Assessments required pre-randomisation

             -  Complete history and physical examination (within 4 weeks before randomisation)

             -  Haematology (Hb, WBC or ANC, platelets) &amp; Biochemistry [serum bilirubin,
                creatinine, alkaline phosphatase] (within 4 weeks before randomisation)

             -  Mammogram, Chest X-ray, liver ultrasound, bone scan (at a maximum 00 months prior
                to diagnosis of breast cancer). In case of clinical symptoms metastatic disease has
                to be excluded before randomisation by the appropriate investigations

             -  Collection of tissue blocks for the central tumour banks at Glasgow Royal Infirmary
                (for sites managed by ICCG) land Studienzentrale in Frankfurt (for sites managed by
                GBG)

        2. Treatment

           Treatment must begin within 14 working days after randomisation and within 12 weeks of
           day 1 of the last cycle of adjuvant chemotherapy. Radiotherapy should be given according
           to local policy (concomitant trial treatment and radiotherapy is permitted). Patients
           will be randomised 2: 1 (in favour of celecoxib) to receive:

           Two Placebo capsules twice daily with food or Two Celecoxib 200mg capsules twice daily
           (800mg per day) with food The duration of celecoxib/placebo treatment is 2 years. In
           addition all postmenopausal ER + and/or PgR+ postmenopausal patients will receive
           exemestane (25mg daily) for 5 years. The start of the treatment will be at same time as
           starting celecoxib or placebo.

        3. Routine Follow up Visits During the course of the trial all patients will be followed up
           every 3 months in the first year, every 6 months in !years 2 and 3 and annually from
           year 4 onwards.

           Follow up Assessments

             -  Clinical examination and history

             -  Haematology &amp; biochemistry

             -  Metastatic screen -additional tests/investigations (eg. Bone/liver scan etc) are at
                the investigators discretion if clinically indicated.

             -  Serious Adverse Events

        4. Follow up upon relapse Any relapse requires treatment to be stopped and patients should
           have the minimum tests carried out as described in section (c) above.

      Relapse is categorized as ipsilateral breast or axillary nodal relapse [loco regional]
      distant relapse (including supraclavicular nodes) [distant] and contralateral breast disease
      (malignant) [2nd primary]. In the event of tumor recurrence the relevant recurrence form
      should be completed and the trials office notified within 4 weeks.

      All patients will be followed up long term irrespective o whether they have been withdrawn
      from treatment prematurely.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2005</start_date>
  <completion_date type="Actual">March 2019</completion_date>
  <primary_completion_date type="Actual">March 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Free Survival (DFS) Benefit of Two Years Adjuvant Therapy With the COX-2 Inhibitor Celecoxib Compared With Placebo in Primary Breast Cancer Patients.</measure>
    <time_frame>Patients will be followed up to 10 years. DFS will be calculated from date of randomization until the date of first documented DFS event, this will be assessed at 2 and 5 years</time_frame>
    <description>From time of randomisation to the date of first event; with events contributing to the analysis defined as loco-regional and distant breast cancer recurrence, new primary breast cancer (ipsilateral or contralateral) and death without disease relapse (intercurrent death)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Date of randomisation until the date of death from any cause or censored at the date the patient was last seen alive, this will be assessed at 2 and 5 years</time_frame>
    <description>First local recurrence and first distant recurrence will be recorded on separate parts of the CRF. In the event of local progression, all patients must be followed up for distant recurrence, second malignancy and survival. Similarly in the case of second malignancy, the appropriate CRF should be completed and patients should REACT Protocol, Version 39, dated 01.11.2016 Page 34 of 48 continue to be followed for disease progression and where possible the relation of any subsequent disease progression and/or death due to the primary or second cancer should be established.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Incidence of Second Primary Breast Cancers</measure>
    <time_frame>From randomisation until a second primary breast cancer is diagnosed. Patients will be followed up to 10 years.</time_frame>
    <description>Any malignant contralateral breast disease will be included and recorded as a second primary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular Mortality</measure>
    <time_frame>Patients are followed up to 10 years, any deaths within this timeframe with cardiovascular involvement reported are included in the analysis.</time_frame>
    <description>Number of deaths recorded as having cardiovascular involvement are reported by treatment group.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2639</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Celecoxib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm will receive 400mg of celecoxib once daily. In addition, Hormone Receptor (+) patients will receive endocrine treatment according to local practice.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients in this arm will receive 2 tablets once daily. In addition Hormone Receptor (+) patients will receive endocrine treatment according to local practice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>Patients will receive 400mg of Celecoxib once daily for two years or until disease progression (if before the two years limit) or until development of unacceptable toxicities. In addition ER(+) patients will receive endocrine treatment according to local practice.</description>
    <arm_group_label>Celecoxib</arm_group_label>
    <other_name>Celebrex, Onsenal, Celebra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Two capsules once daily with food</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Completely resected (greater or equal 1mm), histologically or cytologically proven
             unilateral breast cancer

          2. Female greater or equal 18 years of age

          3. If (neo) adjuvant chemotherapy received, patient must have received at least 4 cycles.
             Chemotherapy must be completed prior to study entry

          4. Hormone Receptor negatives must have received prior chemotherapy

          5. Study entry must be within any of the following timelines: 3 months of the end of
             definitive breast surgery OR between 3 weeks and 4 months after day 1 of the last
             cycle of adjuvant chemotherapy OR 6 weeks of the end of radiotherapy.

          6. WHO performance status 0 or 1

          7. Pre-treatment haematology and biochemistry values within acceptable local limits:
             Haemoglobin, white blood cell greater or equal to 3.0 x 109/l or absolute neutrophil
             count greater or equal to 1.51 x 109/l, Platelets greater or equal to 100 x 109/l,
             Serum bilirubin less than 1.5 x upper normal limit , Alkaline phosphatase less or
             equal to 1.5 x upper normal limit , Serum creatinine less than 1.5 x upper normal
             limit

          8. Negative pregnancy test for patients with child-bearing potential

          9. Normal baseline ECG and clinical cardiovascular assessment after completion of all
             (neo) adjuvant chemotherapy

         10. No previous or current evidence for metastatic disease

         11. Be accessible for and consent to long term follow-up

         12. Written informed consent prior to commencement of specific protocol procedures must be
             obtained and documented according to the local regulatory requirements

        Exclusion Criteria

          1. Patients with node negative, T1, Grade 1 breast cancer

          2. Unresectable, metastatic or bilateral breast cancer

          3. Active or previous peptic ulceration or gastrointestinal bleeding in the last year

          4. Active or previous history of inflammatory bowel disease

          5. A past history of adverse reaction/hypersensitivity to NSAIDs, including celecoxib and
             salicylates, or sulphonamides

          6. On current or planned chronic NSAIDs therapy (except low dose aspirin 100 mg four
             times per day or 325mg once daily).

          7. Current or long-term use of oral corticosteroids

          8. Known or suspected congestive heart failure (greater than New York Heart Association
             I) and/or coronary heart disease, previous history of myocardial infarction,
             uncontrolled arterial hypertension (ie BP greater than 160/90mmHg) under treatment
             with two anti-hypertensive drugs, rhythm abnormalities requiring permanent treatment.

          9. Patients with diabetes controlled by diet and oral medication are eligible for the
             study however patients with insulin dependent diabetes are excluded

         10. Past history of stroke/Transient ischaemic attack, symptomatic peripheral vascular
             disease or carotid disease

         11. Previously entered into an adjuvant chemotherapy trial for which approval for entry
             into REACT has not been granted

         12. ER receptor status unknown, Human epidermal growth factor receptor 2 or FISH positive,
             or Human epidermal growth factor receptor 2 status unknown

        14. Hormone Receptor negative and not received (neo)adjuvant chemotherapy 15. Use of
        hormone replacement therapy within the last 6 weeks 16. Pregnant or lactating women or
        women of childbearing potential unwilling/unable to use non-hormonal contraception 17. No
        previous or concomitant malignancies except adequately treated squamous cell / basal cell
        carcinoma of the skin, in situ carcinoma of the cervix or ductal carcinoma in situ/lobular
        carcinoma in situ of the breast, unless there has been a disease-free interval of 10 years
        or more 18. Psychiatric or addictive disorders which could preclude obtaining informed
        consent 19. Clinical evidence of severe osteoporosis and/or history of osteoporotic
        fracture
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles R Coombes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <link>
    <url>http://www1.imperial.ac.uk/cancer/iccg/breast/react/</url>
    <description>REACT Trial Information linked to the sponsor webpage</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 15, 2015</study_first_submitted>
  <study_first_submitted_qc>April 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2015</study_first_posted>
  <results_first_submitted>May 26, 2020</results_first_submitted>
  <results_first_submitted_qc>June 11, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 23, 2020</results_first_posted>
  <last_update_submitted>June 11, 2020</last_update_submitted>
  <last_update_submitted_qc>June 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary Breast Cancer</keyword>
  <keyword>Celecoxib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 1, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/27/NCT02429427/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 11, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/27/NCT02429427/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Celecoxib</title>
          <description>Patients in this arm will receive 400mg of celecoxib once daily. In addition, Hormone Receptor (+) patients will receive endocrine treatment according to local practice.
Celecoxib: Patients will receive 400mg of Celecoxib once daily for two years or until disease progression (if before the two years limit) or until development of unacceptable toxicities. In addition ER(+) patients will receive endocrine treatment according to local practice.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Patients in this arm will receive 2 tablets once daily. In addition Hormone Receptor (+) patients will receive endocrine treatment according to local practice.
Placebo: Two capsules once daily with food</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1763"/>
                <participants group_id="P2" count="876"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1392"/>
                <participants group_id="P2" count="697"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="371"/>
                <participants group_id="P2" count="179"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="220"/>
                <participants group_id="P2" count="92"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Celecoxib</title>
          <description>Patients in this arm will receive 400mg of celecoxib once daily. In addition, Hormone Receptor (+) patients will receive endocrine treatment according to local practice.
Celecoxib: Patients will receive 400mg of Celecoxib once daily for two years or until disease progression (if before the two years limit) or until development of unacceptable toxicities. In addition ER(+) patients will receive endocrine treatment according to local practice.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Patients in this arm will receive 2 tablets once daily. In addition Hormone Receptor (+) patients will receive endocrine treatment according to local practice.
Placebo: Two capsules once daily with food</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1763"/>
            <count group_id="B2" value="876"/>
            <count group_id="B3" value="2639"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.2" lower_limit="48.7" upper_limit="62.6"/>
                    <measurement group_id="B2" value="55.3" lower_limit="48.6" upper_limit="63.0"/>
                    <measurement group_id="B3" value="55.2" lower_limit="48.6" upper_limit="62.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1763"/>
                    <measurement group_id="B2" value="876"/>
                    <measurement group_id="B3" value="2639"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Ethnicity</title>
              <category_list>
                <category>
                  <title>Caucasian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1689"/>
                    <measurement group_id="B2" value="848"/>
                    <measurement group_id="B3" value="2537"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black Caribbean</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black African</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Disease Free Survival (DFS) Benefit of Two Years Adjuvant Therapy With the COX-2 Inhibitor Celecoxib Compared With Placebo in Primary Breast Cancer Patients.</title>
        <description>From time of randomisation to the date of first event; with events contributing to the analysis defined as loco-regional and distant breast cancer recurrence, new primary breast cancer (ipsilateral or contralateral) and death without disease relapse (intercurrent death)</description>
        <time_frame>Patients will be followed up to 10 years. DFS will be calculated from date of randomization until the date of first documented DFS event, this will be assessed at 2 and 5 years</time_frame>
        <population>Intention To Treat: This population includes all patients entered into the study in the treatment group they were allocated to regardless of whether they do not start treatment, take the wrong treatment or deviate in any way from the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib</title>
            <description>Patients in this arm will receive 400mg of celecoxib once daily. In addition, Hormone Receptor (+) patients will receive endocrine treatment according to local practice.
Celecoxib: Patients will receive 400mg of Celecoxib once daily for two years or until disease progression (if before the two years limit) or until development of unacceptable toxicities. In addition ER(+) patients will receive endocrine treatment according to local practice.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients in this arm will receive 2 tablets once daily. In addition Hormone Receptor (+) patients will receive endocrine treatment according to local practice.
Placebo: Two capsules once daily with food</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Free Survival (DFS) Benefit of Two Years Adjuvant Therapy With the COX-2 Inhibitor Celecoxib Compared With Placebo in Primary Breast Cancer Patients.</title>
          <description>From time of randomisation to the date of first event; with events contributing to the analysis defined as loco-regional and distant breast cancer recurrence, new primary breast cancer (ipsilateral or contralateral) and death without disease relapse (intercurrent death)</description>
          <population>Intention To Treat: This population includes all patients entered into the study in the treatment group they were allocated to regardless of whether they do not start treatment, take the wrong treatment or deviate in any way from the protocol.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1763"/>
                <count group_id="O2" value="876"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2 Year DFS rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91" lower_limit="90" upper_limit="93"/>
                    <measurement group_id="O2" value="90" lower_limit="87" upper_limit="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 Year DFS rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84" lower_limit="82" upper_limit="86"/>
                    <measurement group_id="O2" value="83" lower_limit="81" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.751</p_value>
            <method>Log Rank</method>
            <method_desc>Analysis stratified by oestrogen receptor status and country.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
            <estimate_desc>Analysis stratified by oestrogen receptor status and country.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>First local recurrence and first distant recurrence will be recorded on separate parts of the CRF. In the event of local progression, all patients must be followed up for distant recurrence, second malignancy and survival. Similarly in the case of second malignancy, the appropriate CRF should be completed and patients should REACT Protocol, Version 39, dated 01.11.2016 Page 34 of 48 continue to be followed for disease progression and where possible the relation of any subsequent disease progression and/or death due to the primary or second cancer should be established.</description>
        <time_frame>Date of randomisation until the date of death from any cause or censored at the date the patient was last seen alive, this will be assessed at 2 and 5 years</time_frame>
        <population>Intention To Treat: This population includes all patients entered into the study in the treatment group they were allocated to regardless of whether they do not start treatment, take the wrong treatment or deviate in any way from the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib</title>
            <description>Patients in this arm will receive 400mg of celecoxib once daily. In addition, Hormone Receptor (+) patients will receive endocrine treatment according to local practice.
Celecoxib: Patients will receive 400mg of Celecoxib once daily for two years or until disease progression (if before the two years limit) or until development of unacceptable toxicities. In addition ER(+) patients will receive endocrine treatment according to local practice.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients in this arm will receive 2 tablets once daily. In addition Hormone Receptor (+) patients will receive endocrine treatment according to local practice.
Placebo: Two capsules once daily with food</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>First local recurrence and first distant recurrence will be recorded on separate parts of the CRF. In the event of local progression, all patients must be followed up for distant recurrence, second malignancy and survival. Similarly in the case of second malignancy, the appropriate CRF should be completed and patients should REACT Protocol, Version 39, dated 01.11.2016 Page 34 of 48 continue to be followed for disease progression and where possible the relation of any subsequent disease progression and/or death due to the primary or second cancer should be established.</description>
          <population>Intention To Treat: This population includes all patients entered into the study in the treatment group they were allocated to regardless of whether they do not start treatment, take the wrong treatment or deviate in any way from the protocol.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1763"/>
                <count group_id="O2" value="876"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2 Year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="96" upper_limit="97"/>
                    <measurement group_id="O2" value="96" lower_limit="95" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 Year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" lower_limit="89" upper_limit="92"/>
                    <measurement group_id="O2" value="91" lower_limit="88" upper_limit="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.781</p_value>
            <method>Log Rank</method>
            <method_desc>Analysis is stratified for oestrogen receptor status and country.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
            <estimate_desc>Analysis is stratified for oestrogen receptor status and country.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Incidence of Second Primary Breast Cancers</title>
        <description>Any malignant contralateral breast disease will be included and recorded as a second primary</description>
        <time_frame>From randomisation until a second primary breast cancer is diagnosed. Patients will be followed up to 10 years.</time_frame>
        <population>Intention To Treat: This population includes all patients entered into the study in the treatment group they were allocated to regardless of whether they do not start treatment, take the wrong treatment or deviate in any way from the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib</title>
            <description>Patients in this arm will receive 400mg of celecoxib once daily. In addition, Hormone Receptor (+) patients will receive endocrine treatment according to local practice.
Celecoxib: Patients will receive 400mg of Celecoxib once daily for two years or until disease progression (if before the two years limit) or until development of unacceptable toxicities. In addition ER(+) patients will receive endocrine treatment according to local practice.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients in this arm will receive 2 tablets once daily. In addition Hormone Receptor (+) patients will receive endocrine treatment according to local practice.
Placebo: Two capsules once daily with food</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Incidence of Second Primary Breast Cancers</title>
          <description>Any malignant contralateral breast disease will be included and recorded as a second primary</description>
          <population>Intention To Treat: This population includes all patients entered into the study in the treatment group they were allocated to regardless of whether they do not start treatment, take the wrong treatment or deviate in any way from the protocol.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1763"/>
                <count group_id="O2" value="876"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiovascular Mortality</title>
        <description>Number of deaths recorded as having cardiovascular involvement are reported by treatment group.</description>
        <time_frame>Patients are followed up to 10 years, any deaths within this timeframe with cardiovascular involvement reported are included in the analysis.</time_frame>
        <population>Safety population: This population includes all patients who start treatment, patients will be analysed by the treatment they received regardless of the group they were allocated to.</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib</title>
            <description>Patients in this arm will receive 400mg of celecoxib once daily. In addition, Hormone Receptor (+) patients will receive endocrine treatment according to local practice.
Celecoxib: Patients will receive 400mg of Celecoxib once daily for two years or until disease progression (if before the two years limit) or until development of unacceptable toxicities. In addition ER(+) patients will receive endocrine treatment according to local practice.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients in this arm will receive 2 tablets once daily. In addition Hormone Receptor (+) patients will receive endocrine treatment according to local practice.
Placebo: Two capsules once daily with food</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiovascular Mortality</title>
          <description>Number of deaths recorded as having cardiovascular involvement are reported by treatment group.</description>
          <population>Safety population: This population includes all patients who start treatment, patients will be analysed by the treatment they received regardless of the group they were allocated to.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1755"/>
                <count group_id="O2" value="868"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the time of randomisation until 30 days after the discontinuation of celecoxib/placebo (i.e. 2 years or sooner if patient discontinued early).</time_frame>
      <desc>Only adverse events classed as grade 2 or above were collected. Adverse Events and SAEs were assessed in the Safety Population and All-Cause Mortality was assessed for all enrolled participants</desc>
      <group_list>
        <group group_id="E1">
          <title>Celecoxib</title>
          <description>Patients in this arm will receive 400mg of celecoxib once daily. In addition, Hormone Receptor (+) patients will receive endocrine treatment according to local practice.
Celecoxib: Patients will receive 400mg of Celecoxib once daily for two years or until disease progression (if before the two years limit) or until development of unacceptable toxicities. In addition ER(+) patients will receive endocrine treatment according to local practice.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Patients in this arm will receive 2 tablets once daily. In addition Hormone Receptor (+) patients will receive endocrine treatment according to local practice.
Placebo: Two capsules once daily with food</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="203" subjects_at_risk="1763"/>
                <counts group_id="E2" subjects_affected="104" subjects_at_risk="876"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="148" subjects_at_risk="1755"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1755"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Thrombocytopenic purpura</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute cardiac event</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Cardiomegaly</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Chest pain - cardiac</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Ventricular septal defect</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="1755"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1755"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Condition aggravated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Fibrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Perforated ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Suprapubic pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="1755"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="1755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Mastitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1755"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Ophthalmic herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Uterine infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Postoperative wound complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Wound necrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="1755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1755"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Adenoid cystic carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Adrenal adenoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Benign ovarian tumour</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Breast cancer recurrent</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Gallbladder cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1755"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Metastasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Second primary malignancy</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1755"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Vulval cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Nervous system disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Neurological symptom</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1755"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="1755"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Psychiatric symptom</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Adnexal torsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Breast necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1755"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Alveolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Swelling of eyelid</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abortion induced</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Breast reconstruction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1755"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Cholecystectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Hysterosalpingo-oophorectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Oophorectomy bilateral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Surgery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1755"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="298" subjects_at_risk="1755"/>
                <counts group_id="E2" subjects_affected="151" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA">Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="128" subjects_at_risk="1755"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="106" subjects_at_risk="1755"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="178" subjects_at_risk="1755"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof Charles Coombes</name_or_title>
      <organization>Imperial College London</organization>
      <phone>+44 20 7594 2135</phone>
      <email>c.coombes@imperial.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

